Anticoagulation offers no clear benefit in patients with device-detected atrial fibrillation
A Win Ratio analysis confirmed the primary result of the NOAH—AFNET 6 trial and did not find an advantage of anticoagulation with edoxaban over no anticoagulation in patients with device-detected atrial fibrillation. Clinical ...
Sep 1, 2025
0
15









